Bank of New York Mellon Corp Purchases 87,089 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Bank of New York Mellon Corp raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 48.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 265,514 shares of the biopharmaceutical company’s stock after acquiring an additional 87,089 shares during the period. Bank of New York Mellon Corp owned approximately 0.47% of Agios Pharmaceuticals worth $8,725,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. KBC Group NV lifted its stake in Agios Pharmaceuticals by 30.5% in the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 611 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock valued at $539,000 after buying an additional 688 shares during the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 10.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,092 shares of the biopharmaceutical company’s stock valued at $397,000 after purchasing an additional 1,150 shares during the last quarter. Finally, Quest Partners LLC raised its position in shares of Agios Pharmaceuticals by 139.6% in the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,283 shares during the last quarter.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AGIO. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank increased their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $30.93 on Friday. The stock has a fifty day moving average price of $33.70 and a 200 day moving average price of $41.83. The company has a market cap of $1.77 billion, a PE ratio of 2.73 and a beta of 0.90. Agios Pharmaceuticals, Inc. has a 1-year low of $27.14 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.